• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$99.90 -$0.09 (-0.09%)

REAL-TIME: Last trade at

C.R. Bard, Inc.

NYSE:BCR

Covidien Prices Senior Notes - Analyst Blog

The Zacks Analyst Blog Highlights: AngioDynamics, J.P. Morgan, Bank of America, KeyCorp and CR Bard

Angio Completes Key Acquisition - Analyst Blog

Covidien Launches HALO90 ULTRA - Analyst Blog

Covidien Completes Acquisition - Analyst Blog

The Zacks Analyst Blog Highlights: Covidien, General Electrical, Becton, Dickinson and Company, John

Weekly CFO Sells Highlight: EL, ACTU, AGN, BCR, RHT, ZNGA

Find Outperforming Stocks in a Down Market! - Press Releases

Covidien Teams Up with GE Health - Analyst Blog

Covidien Buys PolyTouch Medical - Analyst Blog

Is C.R. Bard Going to Burn You?

Covidien's 2Q Beats, Profit Rises - Analyst Blog

CR Bard Beats EPS Est., Lags Rev - Analyst Blog

C.R. Bard Beats Analyst Estimates on EPS

AngioDynamics Ships NanoKnife Again - Analyst Blog

MARKET SNAPSHOT: U.S. Stock Gains Hinge On Apple, Blue-chip Results

Covidien to Acquire Oridion Systems - Analyst Blog

ANGO Mixed, Adjusts View - Analyst Blog

Covidien Takes Over superDimension - Analyst Blog

Has CR Bard Become the Perfect Stock?

New Surgical Devices from Covidien - Analyst Blog

The Zacks Analyst Blog Highlights: Applied Materials, Covidien, Johnson & Johnson, Becton Dickinson

Covidien Intros HALO60 Catheter - Analyst Blog

FDA Nod for Covidien's Solitaire - Analyst Blog

How Does Boston Scientific Boost its Returns?

AngioDynamics' NeverTouch Kit OK'd - Analyst Blog

Earnings Scorecard: C.R. Bard - Analyst Blog

Earnings Scorecard: Covidien - Analyst Blog

AngioDynamics to Buy Navilyst - Analyst Blog

C.R. Bard Beats Analyst Estimates on EPS

Bard Tops in 4Q, Charges Crimp Net - Analyst Blog

Covidien's Solitaire Ok'd for Trial - Analyst Blog

Earnings Preview: C.R. Bard - Analyst Blog

AngioDynamics Cuts View on Recall - Analyst Blog

Covidien EPS Tops, Snips Sales View - Analyst Blog

Earnings Preview: Covidien - Analyst Blog

Does Boston Scientific Pass Buffett's Test?

Covidien Recalls Duet TRS - Analyst Blog

Retaining AngioDynamics at Neutral - Analyst Blog

Covidien Wraps up BARRX Buy - Analyst Blog

See More Articles...